Last: | $0.29005 |
---|---|
Change Percent: | 3.32% |
Open: | $0.291 |
Close: | $0.29005 |
High: | $0.3 |
Low: | $0.27 |
Volume: | 58,949 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.29005 | $0.291 | $0.29005 | $0.3 | $0.27 | 58,949 | 04-19-2024 |
$0.301 | $0.31 | $0.301 | $0.31 | $0.2849 | 131,018 | 04-18-2024 |
$0.3 | $0.32 | $0.3 | $0.32 | $0.262 | 260,209 | 04-17-2024 |
$0.305449 | $0.33 | $0.305449 | $0.3368 | $0.285 | 806,885 | 04-16-2024 |
$0.3187 | $0.334 | $0.3187 | $0.334 | $0.31 | 103,193 | 04-15-2024 |
$0.3295 | $0.335 | $0.3295 | $0.335 | $0.3242 | 67,463 | 04-12-2024 |
$0.335 | $0.36 | $0.335 | $0.39 | $0.325 | 1,038,881 | 04-11-2024 |
$0.37 | $0.338 | $0.37 | $0.376 | $0.3149 | 677,524 | 04-10-2024 |
$0.33989 | $0.3249 | $0.33989 | $0.3443 | $0.32 | 230,557 | 04-09-2024 |
$0.334 | $0.3149 | $0.334 | $0.3392 | $0.3108 | 139,241 | 04-08-2024 |
$0.322 | $0.3285 | $0.322 | $0.3398 | $0.3108 | 438,331 | 04-05-2024 |
$0.3399 | $0.365 | $0.3399 | $0.4555 | $0.3305 | 6,490,126 | 04-04-2024 |
$0.35 | $0.359 | $0.35 | $0.375 | $0.341 | 103,312 | 04-03-2024 |
$0.3689 | $0.369099 | $0.3689 | $0.3691 | $0.332 | 16,746 | 04-02-2024 |
$0.369099 | $0.35 | $0.369099 | $0.37 | $0.335 | 45,427 | 04-01-2024 |
$0.364 | $0.3501 | $0.364 | $0.3787 | $0.3405 | 59,856 | 03-29-2024 |
$0.364 | $0.3501 | $0.364 | $0.3787 | $0.3405 | 59,856 | 03-28-2024 |
$0.3468 | $0.35 | $0.3468 | $0.357 | $0.332 | 62,624 | 03-27-2024 |
$0.3451 | $0.36 | $0.3451 | $0.3649 | $0.34 | 76,604 | 03-26-2024 |
$0.36 | $0.36 | $0.36 | $0.379 | $0.3502 | 60,538 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD, a renowned leader in neurodegenerative disease, has joined its scientific advisory board (&...
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the addition ...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signal...